FARMINGTON, Conn., Oct. 28, 2019 /PRNewswire-PRWeb/ -- CaroGen Corporation, a biotechnology company, today announced three distinguished additions to its Scientific Advisory Board:
- Professor Jack R Wands, MD, of Brown University
- Dr. Steve Projan, PhD, FAAM, formerly of MedImmune, Novartis and Wyeth (Pfizer)
- Professor Gil Mor, MD, PhD, of Wayne State University, formerly a professor at Yale University School of Medicine
CaroGen, a spin-off from Yale University School of Medicine, is a developer of first-in-class im-munotherapies based on its transformative and patented AVIDIO (Artificial Virus for Infectious Diseases and Immune-Oncology) technology platform.
"The addition of such highly accomplished scientists to our SAB provides us with the industry leading expertise and experience to maximize the potential of our AVIDIO-based immuno oncolo-gy pipeline," said Bijan Almassian, PhD, CEO and co-founder of CaroGen.
Dr. Jack Wands is the Jeffrey and Kimberly Greenberg-Artemis and Martha Joukowsky Professor in Gastroenterology and Professor of Medical Science at the Brown University Medical School. He founded and developed the Rhode Island Hospital/Brown University Liver Research Center. Dr. Wands received his M.D. with High Honors from the University of Washington School of Medicine. He completed a four-year Fellowship in Internal Medicine at Johns Hopkins, and was Chief Resident in Medicine at Johns Hopkins/Bayview Medical Center (formerly Baltimore City Hospital). A Clinical and Research Fellowship in Gastroenterology were performed at Massachu-setts General Hospital. Dr. Wands is an internationally renowned physician/scientist who has re-ceived a number of awards including two N.I.H. merit awards, Max Planck Merit Award, and a Bristol Myers Squibb unrestricted grant in infectious disease. He is the recipient of 100 U.S. and international patents related to investigative work in hepatology. He is the recipient of several major N.I.H. grants and has published over 400 peer-reviewed manuscripts and has contributed to 56 textbooks.
Dr. Steve Projan, PhD is the Former Head of the Infectious Diseases & Vaccines Innovative Med-icines unit (iMED) at MedImmune, leading a cross-functional team dedicated to the therapeutic area in strategy, prioritization and advancement of the company's infectious disease and vaccine portfo-lio. Prior to Medimmune, Dr. Projan served as Vice President and Global Head of Infectious Dis-eases at the Novartis Institutes for Biomedical Research in Cambridge, MA. He previously spent 15 years at Wyeth (now Pfizer) in roles of increasing responsibility with his last post as Vice Pres-ident and Head of Biological Technologies. Prior to Dr. Projan's work in the industry, he spent 14 years at the Public Health Research Institute and presently has over 110 publications to his cred-it. Dr. Projan received a Bachelor of Science from the Massachusetts Institute of Technology and Masters of Arts and Philosophy in biological sciences and a doctorate in molecular genetics from Columbia University.
Dr. Gil G. Mor, M.D., Ph.D., is the Scientific Director of The C.S. Mott Center for Human Growth and Development at Wayne State University School of Medicine. Dr. Mor is a prominent reproductive and ovarian cancer researcher and formerly was a tenured Professor of Obstetrics and Gynecology and Reproductive Science at Yale University School of Medicine. He directed the Re-productive Immunology Unit and the Translational Research Program "Discovery To Cure" at Ya-le University. Dr. Mor has been the Editor-in-Chief of the American Journal of Reproductive Im-munology since September 2009 and is the President of the American Society for Reproductive Immunology. Dr. Mor is widely published in the area of immunology and reproduction with more than 280 publications and is recipient of several national and international prizes, including the J. Christian Herr Award- and the AJRI Award from the Society for Reproductive Immunology.
About CaroGen Corporation:
CaroGen develops novel immunotherapies for colorectal (CRC) and ovarian cancer using its AVIDIO platform discovered by professor John Rose at Yale School of Medicine. CaroGen has completed in vitro studies on CRC and ovarian cancer and currently is conducing animal efficacy studies in relevant animal modes. The safety and proof-of-concept efficacy studies for AVIDIO based immunotherapy for chronic hepatitis B (HBV) has been validated in relevant animal models.
SOURCE CaroGen Corporation
Share this article